Roche Holding(DE:RHO6)
€54.90+0.65 (+1.20%)
DE:RHO6
Roche Holding stock drug pipeline
€54.90
At close:+0.65 (+1.20%)
Roche Holding (RHO6) Drug Pipeline
20 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Abemaciclib, Gdc-4198, Giredestrant | Breast Cancer | phase1AndPhase2 | Recruiting | A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | Jul 31, 2025 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Abemaciclib, Gdc-4198, Giredestrant | phase1AndPhase2 | Breast Cancer | Recruiting | A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | Jul 31, 2025 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Roche Holding AG (DE:RHO6) have in its pipeline
Roche Holding DE:RHO6 is currently developing the following drugs: Abemaciclib, Gdc-4198, Giredestrant. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

